The international generic pharmaceuticals company, Actavis Group, has launched the oncology product Gemcitabine in EU markets, at patent expiry. This launch represents a significant milestone
The international generic pharmaceuticals company, Actavis Group, has launched the oncology product Gemcitabine in EU markets, at patent expiry. This launch represents a significant milestone
